Jiuzi Holdings, Inc. (JZXN) Secures 100 Bitcoin via Private Placement, Signaling New Phase in Crypto Treasury Deployment
HANGZHOU, China, Oct. 13, 2025 /PRNewswire/ -- Jiuzi Holdings, Inc. (NASDAQ: JZXN,…
Berlin Heals Holding AG Successfully Completes Enrollment in Phase I of the CMIC-III Less Invasive Study
Completed Enrollment in First-In-Human Phase I study of Less Invasive Approach Expected…
Mobix Labs Moves Decisively with All-Cash $1.30 Per Share Offer for Peraso a 53% Premium That Signals New Phase of Growth
53% Premium All-Cash Offer Highlights Mobix Labs’ Momentum and Growth Vision October…
Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinsons Disease and Movement Disorders
– ARV-102 was well tolerated in clinical trials for both healthy volunteers…
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Nave or Resistant R/M-HNSCC
Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients…
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX),…
Organogenesis Provides Update on Second Phase 3 ReNu Study
Company maintains confidence in ReNu as innovative pain management therapy Second Phase…
LANZAJET AND KAZMUNAYGAS (KMG) ANNOUNCE KAZAKHSTAN’S FIRST SUSTAINABLE AVIATION FUEL PROJECT PASSES MAJOR MILESTONE AND ADVANCES TO ENGINEERING AND DESIGN PHASE
As part of New York Climate Week, LanzaJet's CEO addressed the President…
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
Through Week 56 in the SOLARIS trial, there were no suspected or…
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
September 20, 2025 11:00 ET | Source: C4 Therapeutics, Inc. Cemsidomide in…
